Surgery Partners Inc (SGRY)
NASDAQ:SGRY
Want to see SGRY full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.07Last Year’s EPS
0.17Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Neutral — The call conveyed cautious optimism: the company reported solid revenue and EBITDA in line with expectations, strong MSK/robotics momentum, physician recruiting progress and reiterated full‑year guidance, but those positives are counterbalanced by below‑trend case growth, payer mix/provider tax headwinds, rising interest expense and elevated leverage that temper near‑term upside.Company Guidance
Quarterly Financial Performance in Line with Expectations
Net revenue of approximately $811 million; adjusted EBITDA of approximately $102 million (12.6% adjusted EBITDA margin); same‑facility net revenue growth of 4.4%; operating cash flow of ~$12 million (vs ~$6 million prior year).
Strong Musculoskeletal Momentum and Robotics Adoption
Total joints performed in ASCs grew 14.6% year‑over‑year; company operates 73 surgical robots across the portfolio supporting higher‑acuity cases and driving acuity mix improvement.
Physician Recruitment and De Novo Growth
Recruited ~140 physicians in Q1 with concentration in orthopedics, ophthalmology and GI; opened 1 de novo in the quarter and 9 de novos over the trailing 12 months, with additional de novos (5 expected later this year and 7 in pipeline) supporting attractive returns on capital.
Sequential Cost Management Progress
Supply expense improved to ~27.2% of net revenue and SWB improved to ~30.5% of revenue versus prior year; management cited sequential improvements in labor and supply cost metrics and ongoing cost containment initiatives to drive margin expansion.
Reiterated Full‑Year Guidance and Capital Discipline
Reiterated FY2026 revenue guidance of $3.35B–$3.45B and adjusted EBITDA guidance of at least $530M; discipline on share repurchases and targeted ~$200M annual M&A deployment (pipeline active); net leverage under credit agreement ~4.3x with plan for gradual deleveraging.
SGRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SGRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 02, 2026 | $15.88 | $13.92 | -12.34% |
Nov 10, 2025 | $21.50 | $16.04 | -25.40% |
Aug 05, 2025 | $22.22 | $22.14 | -0.36% |
May 12, 2025 | $22.16 | $23.26 | +4.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Surgery Partners Inc (SGRY) report earnings?
Surgery Partners Inc (SGRY) is schdueled to report earning on Aug 04, 2026, Before Open (Confirmed).
What is Surgery Partners Inc (SGRY) earnings time?
Surgery Partners Inc (SGRY) earnings time is at Aug 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGRY EPS forecast?
SGRY EPS forecast for the fiscal quarter 2026 (Q2) is 0.07.